The current JAMA issue examines the process and potential flaws of society clinical practice guidelines -a timely commentary as we await the 2015 ACR RA treatment guidelines first presented at the 2014 ACR meeting in Boston and slated for upcoming publication in Arthritis & Rheumatology
All News
The CDC has released data from the NHANES (National Health and Nutrition Examination Survey) analysis of 2005-2010 data regarding the population frequency of osteoporosis and osteopenia.
In a study that compared seropositive (RF+, CCP+) and seronegative RA with healthy participants, the frequency of thyroid antibodies was assessed.
A recent study published in the journal Patient Preference and Adherence examined insured patients from the Optum Research Database who had moderate to severe plaque psoriasis and queried them about their satisfaction with therapy.
Methotrexate was first introduced in 1955 for leukemia and in 1986 became FDA approved for the treatment of adults with severe, active, rheumatoid arthritis or children with active polyarticular-course juvenile RA.
Using statistics gathered by the NIH in 2012, the National Health Interview Survey of 8781 adults showed self-reported chronic pain affects 25.3 million adults, or 11.2% of the populatoin.
In reviewing submitted abstracts for the 2014 ACR meeting, I was surprised by several abstracts focusing on neutropenia in patients receiving rituximab.
A recent survey by AmericanEHR Partners and the AMA of 940 physicians, physician assistants and nurse practitioners showed most physicians are dissatisfied with their EHR systems.
Are the benefits of androgen supplementation in older men overstated? Might the risks be understated?
Neutrophil extracellular traps (NETs) are first line defense tools used to trap microbial pathogens.
Since publication of the Jupiter trial that showed statin effects may include the lowering of C-reactive protein levels and inflammation, there have been several efforts to study the adjunctive effects of statins in rheumatoid arthritis treatment.
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Wang and coworkers from the Rochester Epidemiology Project presented their findings at the annual Spondyloarthritis Research and Treatment Network.(SPARTAN) in Denver, CO.
A new expanded cardiovascular (CV) risk calculator for use in patients with rheumatoid arthritis (RA) has been developed to take into account disease-specific factors that can worsen risk, researchers reported.
In July 2015, RheumNow published 73 tweets about impactful news, research and teaching points that I feel will have an impact on the rheumatology community. We had a reach (impressions) of 49,900, 63 mentions, and 1277 visits to RheumNow.com to check out what we publish.
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
An estimated 250 people have filed lawsuits against Lilly claiming the company failed to warn users of Cymbalta that they may suffer withdrawal symptoms if the drug was stopped abruptly, including suicidal thoughts and electric shock-like sensations.
The European Scleroderma Trials and Research (EUSTAR) cohort has reported the results of their prospective study to identify onset symptoms and risk factors for skin sclerosis and digital ulcers (DUs) in early onset systemic sclerosis (SSc) patients.
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
Can We Do Better than FAERS? Brian Overstreet (of Adverseevents.com) has written on MedPageToday.com about the current state of adverse event reporting.
